AKATINOL TABLETS

• International Name (active ingredient): Akatinol
• Pharmacological group: Nootropics (Neurometabolic stimulants)
• Manufacturer: Mertz Pharmaceuticals
  
• Country: Germany
• Issuing mode: Group II (without a prescription)
  

Akatinol 10mg #90t
(Memantine hydrochloride)

Release form, packaging: 
30 and 90 tablets of Akatinol memantine coated with a membrane, placed in a package. One tablet contains 10 mg of active substance.
50 or 100 mc dark-colored mini-vials contain drops of Akatinol memantine intended for internal administration. 1 microgram (20 drops) of Akatinol memantine contains 10 mg of active ingredient.

Composition:
Memantine hydrochloride (Memantine hydrochloride)

Clinical-pharmacological group:
Muscle relaxant of central action for the treatment of dementia.

Pharmacological action:
Memantine is a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, which modulates the glutamatergic system. It has a pathogenic effect on the degenerative processes of the central and peripheral nervous system. Memantine regulates ion transport and blocks calcium channels. In addition, it has a neuroprotective effect, regulates membrane potential, improves nerve impulse transmission, cognitive processes, memory and learning ability, improves daily activity.

Pharmacokinetics:
Akatinol memantine is rapidly and completely absorbed after oral administration. The maximum concentration in the plasma is reached in 2-6 hours, in the case of normal functioning of the kidneys, the accumulation of the drug is not observed. The drug is released in two phases. Its half-life in the first phase is 4-9 hours, and in the second phase - 40-65 hours. It is excreted mainly with urine (75-90%).

Indication:
- Degenerative dementia (Alzheimer's type), vascular dementia. mixed type dementia of any severity;
-impairment of memory, concentration and learning ability;
- Cerebral and spinal spastic syndrome developed as a result of brain injury, multiple sclerosis and stroke.

Dosage and Administration:
The dosage regimen of Akatinol memantine is determined individually. It is recommended to start treatment with the minimum effective dose.

Dementia in adults: 
In the first week of treatment, 5 mg/day of Akatinol memantine is prescribed, in the second week - 10 mg/day, in the third week - 15-20 mg/day. If necessary, the weekly dose can be increased by 10-10 mg until the daily dose reaches 30 mg.

Spastic syndrome caused by CNS pathology:
10 mg/day of Akatinol memantine is prescribed in the first week of treatment, 10 mg/day in the second week, 20-30 mg/day in the third week. If necessary, the weekly dose can be increased by 10-10 mg until the daily dose reaches 60 mg. The average maintenance dose is 1-20 mg/day.
The daily dose is equally divided into several doses during the day. The drug is prescribed during meals. The last dose is taken before dinner. In patients with impaired renal function, the dose is determined individually depending on the clinical effect, during the treatment period, monitoring the renal function.
The daily dose in children over 1 year is 500 mg/kg of body weight.

Side effects:  
on the part of the central nervous system: dizziness, fatigue, anxiety, agitation, nausea and a feeling of heaviness in the head and increased intracranial pressure;
From the digestive system:
nausea.

Contraindication:
- increased sensitivity to the drug;
- Marked impairment of kidney function;
- pregnancy and lactation period;

The drug is prescribed with caution in patients suffering from thyrotoxicosis and epilepsy.

Special instructions:
The optimal dose is achieved gradually, with weekly increases in the dose.

Overdose:
There is an increase in side effects. In such a case, gastric lavage, use of activated charcoal, symptomatic therapy are required.

Interaction with other drugs:
Simultaneous use of Akatinol memantine with barbiturates, neuroleptics, anticholinergic drugs, L-DOPA, dopaminergic agonists (bromocriptine) and amantadine can enhance the effect of these drugs. When taken simultaneously with dantrolene or baclofen, memantine can change (enhance or reduce) their effect, therefore the doses of these drugs should be adjusted individually.

Storage conditions
The drug is stored at a temperature of no more than 25^oC, out of the reach of children. 

Shelf life: 3 years.